Los puntos clave no están disponibles para este artículo en este momento.
Targetable IC components are upregulated in the majority of endocrine therapy-resistant LumB cases. Our findings provide rationale for IC inhibition in poor-outcome ER-positive breast cancer.
Anurag et al. (Mon,) studied this question.